<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89969</article-id><article-id pub-id-type="pmcid-ver">PMC89969.1</article-id><article-id pub-id-type="pmcaid">89969</article-id><article-id pub-id-type="pmcaiid">89969</article-id><article-id pub-id-type="pmid">10858338</article-id><article-id pub-id-type="doi">10.1128/aac.44.7.1832-1837.2000</article-id><article-id pub-id-type="publisher-id">1027</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients  Enrolled in a Phase III Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jackson</surname><given-names initials="KA">Kimberley A.</given-names></name><xref ref-type="aff" rid="N0x8a5a460.0x9c96ba8">1</xref><xref ref-type="author-notes" rid="FN151">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosenbaum</surname><given-names initials="SE">Sara E.</given-names></name><xref ref-type="aff" rid="N0x8a5a460.0x9c96ba8">1</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kerr</surname><given-names initials="BM">Bradley M.</given-names></name><xref ref-type="aff" rid="N0x8a5a460.0x9c96ba8">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pithavala</surname><given-names initials="YK">Yazdi K.</given-names></name><xref ref-type="aff" rid="N0x8a5a460.0x9c96ba8">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yuen</surname><given-names initials="G">Geoffrey</given-names></name><xref ref-type="aff" rid="N0x8a5a460.0x9c96ba8">2</xref><xref ref-type="author-notes" rid="FN152">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dudley</surname><given-names initials="MN">Michael N.</given-names></name><xref ref-type="aff" rid="N0x8a5a460.0x9c96ba8">1</xref><xref ref-type="author-notes" rid="FN153">&#167;</xref></contrib></contrib-group><aff id="N0x8a5a460.0x9c96ba8"> Department of Applied Pharmaceutical Science, University of Rhode Island, Kingston, Rhode Island,<sup>1</sup> and  Agouron Pharmaceuticals, La Jolla, California<sup>2</sup></aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Department of Applied Pharmaceutical Science, University of Rhode Island, 41 Lower College Rd., Kingston, RI 02881. Phone: (401) 874-5021. Fax: (401) 874-2181. E-mail: <email>sarar@uri.edu</email>.</p></fn><fn id="FN151"><label>&#8224;</label><p>Present address: Globomax, Hanover, Md.</p></fn><fn id="FN152"><label>&#8225;</label><p>Present address: Glaxo Wellcome Inc., Research Triangle Park, N.C.</p></fn><fn id="FN153"><label>&#167;</label><p>Present address: Microcide Pharmaceuticals, Mountain View, Calif.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2000</year></pub-date><volume>44</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">2486</issue-id><fpage>1832</fpage><lpage>1837</lpage><history><date date-type="received"><day>14</day><month>12</month><year>1999</year></date><date date-type="rev-request"><day>26</day><month>2</month><year>2000</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-14 01:25:31.127"><day>14</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac001832.pdf"/><abstract><p>A population pharmacokinetic analysis was conducted on nelfinavir in patients infected with human immunodeficiency virus (HIV) who were enrolled in a phase III clinical trial. The data consisted of 509 plasma concentrations from 174 patients who received nelfinavir at a dose of 500 or 750 mg three times a day. The analysis was performed using nonlinear mixed-effect modeling as implemented in NONMEM (version 4.0; double precision). A one-compartment model with first-order absorption best described the data. The timing and small number of early postdose blood levels did not allow accurate estimation of volume of distribution (<italic>V/F</italic>) and the absorption rate constant (<italic>k<sub>a</sub></italic>). As a result, two models were used to analyze the data: model 1, in which oral clearance (CL/<italic>F</italic>), <italic>V/F</italic>, and <italic>k<sub>a</sub></italic> were estimated, and model 2, in which <italic>V/F</italic> and <italic>k<sub>a</sub></italic> were fixed to known values and only CL/<italic>F</italic> was estimated. Estimates of CL/<italic>F</italic> ranged from 41.9 to 45.1 liters/h, values in close agreement with previous studies. Neither body weight, age, sex, race, dose level, baseline viral load, metabolite-to-parent drug plasma concentration ratio, history of liver disease, nor elevated results of liver function tests appeared to be significant covariates for clearance. The only significant covariate-parameter relationship was concomitant use of fluconazole on CL/<italic>F</italic>, which was associated with a modest reduction in interindividual variability of CL/<italic>F</italic>. Patients who received concomitant therapy with fluconazole had a statistically significant reduction in nelfinavir CL/<italic>F</italic> of 26 to 30%. Since serious dose-limiting toxicity and concentration-related toxicities are not apparent for nelfinavir, this effect of fluconazole is unlikely to be of clinical significance.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>